Changes in Beneficial Ownership · 4
Establishment Labs Holdings Inc.
ESTANASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
wk-form4_1783715174.xml
Filing details
- Report period
- 2026-04-24
- Issuer
- ESTABLISHMENT LABS HOLDINGS INC.
- Issuer CIK
- 0001688757
- Trading symbol
- ESTA
Reporting owner 1
- Name
- LEWIN NICHOLAS SHERIDAN
- Reporting owner CIK
- 0001398327
- Relationship
- Director
- Address
- C/O MOTIVA USA LLC, 16192 COASTAL HIGHWAY, LEWES, DE, 19958
Non-derivative holdings
| Security | Amount owned | Ownership | Nature of ownership |
|---|---|---|---|
| Common Shares | 19,090 | I | See Footnote[F1] |
| Common Shares | 1,079,960 | D |
Table key
- I
- Indirect
- D
- Direct
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy) | 66.28 | 2026-04-24 | A · Form 4[F2] | 19,561 | A | 0 | [F3] | 2036-04-24 | Common Shares | 19,561 | 19,561 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- The shares are held by the Reporting Person's spouse.↩ 1
- F2
- Represents an award of stock units under the Issuer's 2018 Equity Incentive Plan.↩ 1
- F3
- One-fourth of the shares subject to the option shall vest on April 24, 2027 and each one-year anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date.↩ 1
Signature 1
- Signed
- /s/ Cassandra "Sandra" Harris
- Date
- 2026-07-10
Company context
Establishment Labs Holdings Inc. is a global medical device company dedicated to improving women’s health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The company offers a portfolio of solutions for breast health, breast aesthetics, and breast reconstruction in over 100 countries. With five million Motiva® devices delivered to plastic and reconstructive surgeons since 2010, the company’s products have created a new standard for safety and patient satisfaction. The company’s minimally invasive platform consists of Mia Femtech®, a unique minimally invasive experience for breast harmonization, and Preservé™, a breast tissue preserving and minimally invasive technology for primary breast augmentation and primary mastopexy augmentation. GEM® is a next generation minimally invasive system for gluteal ergonomic modeling currently undergoing an IRB approved pivotal study. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Zensor™ is an RFID technology platform used to safely identify implantable devices from outside the body, and includes the company’s first biosensor Zen™, currently part of an IRB approved pivotal study to measure core breast temperature. These solutions are supported by over 200 patent applications in 2